Orthofix International NV (NASDAQ:OFIX)’s share price was down 11.1% during trading on Tuesday . The stock traded as low as $42.02 and last traded at $42.23, with a volume of 263,377 shares changing hands. The stock had previously closed at $47.52.

Several equities analysts recently commented on OFIX shares. Zacks Investment Research lowered Orthofix International NV from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 4th. TheStreet upgraded Orthofix International NV from a “hold” rating to a “buy” rating in a research note on Monday, May 2nd.

The stock has a market capitalization of $774.41 million and a P/E ratio of 84.12. The company has a 50 day moving average of $45.54 and a 200 day moving average of $42.35.

Orthofix International NV (NASDAQ:OFIX) last announced its quarterly earnings data on Monday, August 1st. The medical device company reported $0.41 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.33 by $0.08. The firm had revenue of $104.10 million for the quarter, compared to analysts’ expectations of $102.40 million. During the same quarter in the prior year, the business posted $0.36 earnings per share. Orthofix International NV’s revenue was up 3.1% on a year-over-year basis. Equities research analysts anticipate that Orthofix International NV will post $1.35 EPS for the current fiscal year.

In related news, CEO Brad Mason sold 18,336 shares of the stock in a transaction on Thursday, June 9th. The stock was sold at an average price of $46.00, for a total transaction of $843,456.00. Following the completion of the sale, the chief executive officer now directly owns 160,256 shares in the company, valued at $7,371,776. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Bradley V. Niemann sold 3,402 shares of the stock in a transaction on Wednesday, June 8th. The stock was sold at an average price of $44.70, for a total value of $152,069.40. Following the sale, the insider now owns 25,500 shares of the company’s stock, valued at $1,139,850. The disclosure for this sale can be found here.

Several hedge funds have recently made changes to their positions in the company. California State Teachers Retirement System raised its stake in shares of Orthofix International NV by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 34,774 shares of the medical device company’s stock valued at $1,363,000 after buying an additional 600 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Orthofix International NV during the fourth quarter valued at about $1,443,000. GSA Capital Partners LLP raised its stake in shares of Orthofix International NV by 18.3% in the fourth quarter. GSA Capital Partners LLP now owns 42,609 shares of the medical device company’s stock valued at $1,671,000 after buying an additional 6,601 shares in the last quarter. Russell Frank Co raised its stake in shares of Orthofix International NV by 80.3% in the fourth quarter. Russell Frank Co now owns 43,978 shares of the medical device company’s stock valued at $1,741,000 after buying an additional 19,582 shares in the last quarter. Finally, Diamond Hill Capital Management Inc. raised its stake in shares of Orthofix International NV by 5.6% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 861,860 shares of the medical device company’s stock valued at $33,794,000 after buying an additional 45,984 shares in the last quarter.

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.